SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT00981448

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes

The purpose of this study is to evaluate the effect of zinc supplementation on insulin secretion by genotype of SLC30A8.

NCT00981448 Diabetes
MeSH: Diabetes Mellitus
HPO: Diabetes mellitus

1 Interventions

Name: Zinc acetate

Description: 50mg of elemental zinc to be administered 2 times daily orally for 14 days.

Type: Dietary Supplement

Zinc supplement


Primary Outcomes

Measure: Change in acute insulin response from IVGTT.

Time: 14 days

Secondary Outcomes

Measure: change in insulin sensitivity

Time: 14 days

Measure: change in disposition index

Time: 14 days

Measure: self-report of history of symptoms of anemia or gastrointestinal symptoms during study

Time: 14 days

Measure: change in serum zinc

Time: 14 days

Measure: change in urinary zinc

Time: 14 days

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 rs13266634

Inclusion Criteria: - aged 21-70 years - Amish decent - genotyping of rs13266634 of SLC30A8 gene - previously consented to contact for future studies and future use of DNA Exclusion Criteria: - Subject is a first-degree relative of another subject with the same SLC30A8 genotype - diabetes mellitus (by history, treatment or random BG>200 mg;dl) - gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history.

- rheumatoid arthritis by history - albumin < 3.5 g/dL - hemochromatosis by history - hematocrit <34% - liver disease by history - alanine aminotransferase or aspartate aminotransferase greater than 2.5 times normal - renal failure by history - estimated glomerular filtration rate < 60 mL/min by MDRD equation - use of thiazide diuretic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of systemic corticosteroid and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of highly-active antiretroviral medications - use of antipsychotic medications - use of quinolone antibiotics - use of tetracycline antibiotic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of chelation therapy in the past month - unwilling to withdraw from supplements for 1 week prior to the study and throughout study - abnormal thyroid stimulating hormone (TSH) level - serious disease precluding participation - reported pregnancy or positive urine hCG test - cancer diagnosis in past 2 years - breastfeeding - use of denture adhesive Inclusion Criteria: - aged 21-70 years - Amish decent - genotyping of rs13266634 of SLC30A8 gene - previously consented to contact for future studies and future use of DNA Exclusion Criteria: - Subject is a first-degree relative of another subject with the same SLC30A8 genotype - diabetes mellitus (by history, treatment or random BG>200 mg;dl) - gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history.



HPO Nodes


HPO:
Diabetes mellitus
Genes 326
SOX2 MKRN3 SOX3 MKKS SNORD115-1 SPATA7 CDKN2A HFE CERKL UBR1 PRPF31 LRAT PRSS1 TREX1 PRSS2 IFT140 ARL2BP GLRX5 SLC29A3 MAK AHI1 ABCA4 PDE4D ZBTB20 PDE6A PDE6G ZMPSTE24 IMPDH1 CEL STUB1 SPINK1 RTEL1 PDE6B LEMD3 INS HLA-DQB1 GJB4 IFT172 AMACR KIZ CDHR1 HLA-DRB1 CYP19A1 CFTR DHX38 MAFA GAS1 INSR ZFP57 MC4R GATA3 CTRC GATA6 PDX1 IPW PEX1 BBS1 PWRN1 PEX6 BBS2 DNAJC21 PEX10 CDH23 SRP54 DHDDS NDN PRPF6 GCK NDP KCTD1 AGBL5 GPR101 PTCH1 HNF4A ADAR TTPA TUB SNORD116-1 HESX1 STAT1 STAT3 TULP1 BLK BLM ARL6 IFIH1 TTC8 GJA1 PROM1 NEK2 GJB3 SAG FBN1 NEUROD1 SARS2 PNPLA6 BRCA1 ALMS1 BRAF BRCA2 PROKR2 CLCNKB TINF2 KLHL7 REEP6 FAM161A PIK3R1 GLI2 ABCC8 KCNJ11 RNASEH2C ARNT2 NPAP1 SCAPER FSCN2 DCAF17 AHR PRCD DKC1 FGF8 PLAGL1 AKT2 NOP10 FGFR1 PLCD1 GNAS PWAR1 SEMA4A HERC2 MERTK FOXH1 PLIN1 HYMAI NODAL USH2A CLRN1 CNGB1 CNGA1 EIF2AK3 MOG CDON CA4 IMPG2 PDE11A FOXP3 FOXC2 HJV PROK2 RNASEH2B KRAS TCF4 KLF11 EFL1 HNF1A BEST1 HNF1B PNPLA2 NR2E3 MAGEL2 POC1A OFD1 SLC25A4 USB1 NRL CLIP2 APOA5 CISD2 RNASEH2A CTC1 PTF1A WFS1 GPR35 POLD1 FOS RRM2B POLG AGPAT2 RBP3 WRN SLC19A2 HGSNAT GLIS3 SHH AIRE KIAA1549 FUZ BAZ1B RDH12 POMGNT1 PRPH2 ARHGEF18 DNM1L CP TWNK CPA1 CASR PCARE SAMHD1 TDGF1 AIP CAV1 PSTPIP1 FXN APOE IDH3B PPARG RFC2 XRCC4 WRAP53 SIX3 GTF2IRD1 NSMCE2 PRPF8 DLL1 NHP2 TERC TERT EDA RGR SLC7A14 AR LEP OPA1 LEPR PALB2 POLR3A RHO CRB1 ZIC2 MKRN3-AS1 CRX RLBP1 TTC7A PPP1R3A CNBP MST1 ERGIC1 LHX1 TGIF1 USP8 MLXIPL LIG4 LIMK1 EYS ARL3 LIPE OTX2 IGF1R GTF2I HMGA2 ATP6 TRNC SLC12A3 LMNA COX1 COX2 COX3 GUCA1B IFT88 CYTB SLC16A2 PRPF4 PRPF3 ELMO2 PDE8B VANGL1 SBDS EIF2S3 IER3IP1 ZNF408 CIDEC ND1 ARMC5 ND4 ND5 ND6 PRKACA PRKAR1A NKX2-5 APPL1 TRNE TRNF ROM1 ZFYVE26 PARN CAVIN1 BSCL2 TRNH RP9 RP1 ELN TRNK PAX4 RP2 TRNL1 RPGR ATM HAMP CTNS CTNNB1 C8ORF37 TRNQ TRNS1 TRNS2 POLG2 TRNV TOPORS TRNW KDSR HBB SUFU IL2RA RPE65 DNAJC3 SNRNP200 SNRPN PALLD TBL2 DISP1 EDA2R NEUROG3 TP53 CEP19 SMAD4 PCNT ZNF513